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Cerebral edema and fluid-filled cysts are common accompaniments of brain
tumors. They contribute to the mass effect imposed by the primary tumor and
are often responsible for a patient's signs and symptoms. Cerebral edema sig-
nificantly increases the morbidity associated with tumorbiopsy, excision, radia-
tion therapy, and chemotherapy. Both edema and cyst formation are thought to
result from a deficiency in the blood-brain barrier, with consequent extravasa-
tion of water, electrolytes, and plasma proteins from altered tumor microves-
sels. The resultant expansion of the cerebral interstitial space contributes to the
elevated intracranial pressure observed with brain tumors. Departure from the
typical blood-brain barrier microvascular architecture may only partially
explain the occurrence ofedema and tumor cyst formation. Biochemical media-
tors have also been implicated in vascular extravasation. Vascular permeability
factor or vascular endothelial growth factor (VPF/VEGF) is a protein that has
recently been isolated from a variety of tumors including human brain tumors.
VPFb is an extraordinarily potent inducer of both microvascular extravasation
(edemagenesis) and the formation ofnew blood vessels (angiogenesis). Its role
in tumor growth and progression would therefore appear pivotal. Herein, the
author presents an updated account of the investigation of VPF. Historical and
clinical perspectives of the study and treatment of tumor associated edema are
provided. The efficacy ofhigh-dose dexamethasone in the treatment ofneoplas-
tic brain edema is discussed. A hypothetical role for VPF in edemagenesis is
presented and discussed. It is hoped that an expanded understanding of the
mechanisms responsible for the genesis ofedema will ultimately facilitate ther-
apeutic intervention.
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bAbbreviations used: VPF, vascular permeability factor; CSF, cerebrospinal fluid; ICP, intracranial pres-
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vascular permeability induction; SIADH, syndrome of inappropriate secretion of anti-diuretic hormone,
VBE, vasogenic brain edema; CMR, cell membrane receptor; PDGF, platelet- derived growth factor,
EGF, epidermal growth factor; TAFs, tumor angiogenesis factors; HG-VPF, human glioma-derived vas-
cular permeability factor; IgG, immunoglobulin G; EGTA, ethylene-glycol-bis(J aminoethylether)-N,N'-
tetra-acetic acid; SDS-PAGE, sodium dodecyl sulfate-polyacrylamine gel electrophoresis; VPF, human
vascular permeability factor; VSM, vascular smooth muscle cells; HUVEC, human umbilical vein
endothelial cells; PKC, protein kinase C; VEGF, vascular endothelial growth factor, IL-1, interleukin-1;
IL-2, interleukin-2; PET, positron emission tomography; FGF, fibroblast growth factor; El, edema index;
GFRAP, glial fibrillary acidic growth protein; RAS, reticular activating system; CN, cranial nerve.
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INTRODUCTION: HISTORICAL AND CLINICAL PERSPECTIVE
The word edema is derived from the Greek word for swelling. Early Greek authors
were the first to associate brain swelling with compound skull fractures. Hippocrates'
work, On Injuries ofthe Head, advocated trepanation within the first three days ofinjury
prior to any further deterioration related to inflammation, hemorrhage, or tissue swelling.
In his work, On the Sacred Disease, Hippocrates recognized the associations between
prolonged seizure activity, cerebrovascular engorgement, and consequent brain swelling
[1]. In 1761, Morgagni's workDe Sedibus et Causis Morborum (The Seats and Causes of
Disease), reported the occurrence of vasogenic edema in association with a left capsular
infarction in a patient with aphasia, right hemiplegia, and right hypoesthesia [2]. Monro
further eluded to the occurrence ofvasogenic brain edema in his treatise Observations on
the Structure and Function of the Nervous System which was published in 1783 [3].
Observations in this work formed the basis of the Monro-Kellie hypothesis which, in
essence, recognized that intracranial hemorrhage, tumor, or edema could only be accom-
modated by exclusion of other components of the normal cranial contents (brain, blood,
and cerebrospinal fluid). Samuel Solly, a surgeon at St. Thomas' Hospital, reported in
1847, the occurrence ofcerebral edema in association with infantile hydrocephalus [4]. In
1874, Sir John Bucknill and Daniel Tuke, physicians at the Devon County Lunatic
Asylum, put forth a definition of cerebral edema in their Third Edition ofthe Manual of
Psychological Medicine [5]. It was said: "Oedema ofthe brain, a state in which the tissue
ofthe organ is permeated by waterorserosity".
In 1905, Reichardt furthered our pathological understanding of cerebral edema by
dividing it into "hirnodem", where the swollen brain is soft and water drips from the cut
surface, and "hirnschwellung", where the brain is firm and the cut surface is dry [6]. In
1908, Harvey Cushing recommended a subtemporal craniectomy for decompression of
brain swelling associated with bursting fractures and added that evacuation ofCSF from
the subarachnoid space opened at operation-would facilitate brain relaxation and surgical
exposure [7,8]. One year later, he advocated the use cisternostomy for CSF drainage
when lumbar puncture was contraindicated [9]. Weed and McKibben, working at the
Army Neurosurgical Laboratories of the Johns Hopkins Medical School in 1919, investi-
gated the effects of intravenous solutions of varying osmolalities on the brain. Their
paper in the American Journal ofPhysiology demonstrated that brain bulk in the cat was
increased by intravenous infusion of hypotonic distilled water and decreased by intra-
venous infusion of hypertonic 30% saline or saturated sodium bicarbonate [10]. Another
major therapeutic advance occurred in 1961 when Galicich and French published their
observations on the "Use of dexamethasone in the treatment of cerebral edema resulting
from brain tumors and brain surgery" [11].
In his Presidential Address to the American Association of Neuropathologists, Igor
Klatzo in 1966 advanced an explanation of the pathogenic mechanisms of the two types
of edema [12]. He defined "vasogenic" edema (hirnodem) as an accumulation of water
and plasma constituents outside cells, resulting from injury to the walls ofcerebral blood
vessels. "Cytotoxic" edema (hirnschwellung) was characterized by intracellular swelling
due to a disturbance of cell membrane permeability, and was associated with an intact
blood-brain barrier. In 1967, Fishman defined "interstitial" edema as that resulting from
the transependymal spread of ventricular CSF into the surrounding periventricular white
matter, as seen in the setting of acute obstructive hydrocephalus [13]. Miller further
expanded the classification in 1979 by identifying "hydrostatic" edema as that occurring
when an imbalance in Starling's equilibrium across the blood vessel wall exists [14]. The
latter imbalance results in extravasation of a protein-free plasma ultrafiltrate into the
extracellular space. Similarly, "hypoosmotic" edema is seen in association with free water
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overload. The resulting excess water accumulation occurs in the extracellular compart-
ment initially but is soon followed by cellular imbibition and swelling in both gray and
white matter (Table 1).
Cerebral edema contributes significantly to neurological morbidity in patients with
brain tumors. Patients with intracranial neoplasms typically present with a constellation
of signs and symptoms which are in part determined by the tumors location in the brain,
as well as the extent to which it elevates ICP. The degree of elevation in ICP is in turn
determined by the contribution ofthe primary tumor mass and any associated edema sur-
rounding the lesion. Progressively worsening headache, nausea, vomiting, blurred vision,
double vision, ataxia, seizures, diminished cognitive skills, and depressed level of con-
sciousness are amongst the more typical indicators ofintracranial hypertension (Table 2).
Failure to recognize, diagnose, and treat the underlying cause may result in a patient's
rapid demise.
Edema associated with brain tumors represents an ultrafiltrate of plasma containing
water, electrolytes, and plasma proteins. Edema fluid emanates from the brain tumor
microvasculature (vasogenic) and infiltrates the white matter surrounding the tumor in a
diffuse manner. Passage into the finger-like projections ofsubcortical white matter (white
matter edema) results in a characteristic appearance on CT and MI studies, as the adja-
cent cortex is relatively spared (Figure 1). Similarly, a focal accumulation of cerebral
interstitial tissue fluid can result in the formation of a tumor-associated cyst (Figure 2 ).
Edema and cyst formation result in distortion of intracranial structures, and contribute to
elevation of the intracranial pressure. As a result, vascular extravasation is frequently as
culpable for a brain tumor patients clinical signs and symptoms as the primary intracere-
bral neoplasm.
Vasogenic brain edema iscommonly seen in association with a variety malignant and
benign brain tumors. It results from a flaw in the integrity of the blood-brain barrier. The
blood-brain barrier is both an anatomical and physiological system which normally regu-
lates the entry and egress ofsubstances between the cerebral interstitial and intravascular
Table 1. Classification ofbrain edema.
EdemaType CurrentTerminology Clinical Association
Type I Vasogenic Brain Edema tumor, abscess
Type II Cytotoxic Brain Edema hypoxia, ischemia, toxins
TypeIll Interstitial BrainTumor hydrocephalus
TypeIV Hypoosmotic Brain Edema SIADH, water intoxication,
malignant hypertension
SIADH, syndrome ofinappropriate antidiuretic hormone secretion.
Table 2. Clinical indicators ofelevated intracranial pressure.
Clinical Symptoms Clinical Signs Clinical Pathophysiology
Progressive headache NA dural and vascular traction
Vomiting NA medullary compression
Blurred vision papilledema venous congestion
Double vision paresis ofCN VI compression ofCN VI
Depressed consciousness altered mentation diffuse effecton RAS
Gaitdisturbance wide based, apraxia compression ofcorticobulbar fibers
CN, cranial nerve; RAS reticular activating system.
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Figure 1. CT and MRI of two patients who presented with a history of progressively worsen-
ing headache, vomiting, double vision, and impaired mentation. Enhanced images obtained
using intravenously administered iodinated (CT) or ferromagnetic (MRI) contrast agents reveal
bright regions of contrast extravasation in areas of frank blood-brain barrier disruption. The dark
CT (low beam attenuation) and corresponding bright MRI (high T2 signal intensity) region of
vasogenic brain edema emanates primarily from within the tumor vascular bed (a and b). Spread of
the edema fluid in a centrifugal fashion results in a characteristic finger-like penetration into the
subcortical white matter (a and c). It is evident in both cases that cerebral edema is contributing as
much to the overall mass effect and brain distortion as the primary neoplasm. Notably, within 24
hrs of starting high-dose dexamethasone (10 mg intravenous every 4 hrs), both of these patients
became asymptomatic and were able to undergo an uneventful gross total excisionoftheir tumor.
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Figure 2. MRI images depicting a low grade glioma of the cerebellum. Note the irregular,
brightly enhancing tumor nodule and associated cyst (a). The fluid content of the cyst is best seen
on aT2-weighted MRI image where it is depicted as a bright or high signal intensity (b). As in the
case of diffuse interstitial edema, the cyst is contributing substantially to mass effect. Both edema
and cyst formation are thought to be related but distinct epiphenomena ofmicrovascular extravasa-
tion.
compartments. As such, it provides a critical interface between the brain and essential
blood-born nutrients, including glucose, amino acids, vitamins, minerals, trace elements,
and a-variety of hormonal regulatory signals. The functional components of the blood-
brain barrier occur primarily at the level of the microvascular endothelial cell. The base-
ment membrane, pericyte, and astrocytic foot processes completely invest the cerebral
microvasculature and contribute to barrier integrity by inducing and regulating the
expression ofspecialized endothelial celljunctional characteristics. Ultrastructural exam-
ination of normal brain microvessels in comparison with brain tumor microvessels sup-
ports the hypothesis that altered tumor microvessels account for the abnormal extravasa-
tion offluidandprotein into the interstitial space. However, a focused pathophysiological
explanation for these anatomical observations has not heretofore evolved despite exten-
sive study.
Treatment of brain tumor patients with high-doses of a glucocorticosteroid (dexam-
ethasone) will result in an improvement or resolution of their ICP-related signs and
symptoms. Clinical improvement occurs predictably within 12 to 48 hrs of initiation of
this therapy. This response is of practical significance as it allows the physician, patient
and patient's family, additional time prior to surgery to discuss issues related to the dis-
ease process, surgical therapy, and perioperative care. Furthermore, patients undergoing
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Figure 3. CT images of a patient with a metastatic brain tumor who presented with severe
headache, a left-sided visual field cut, and left-sided weakness. (a) CT image demonstrating
peritumoral vasogenic brain edema and tumor enhancement prior to initiation of dexamethasone
therapy. (b) Partial resolution of both edema and tumor enhancement are evident on a CT per-
formed 24 hrs later. The patient's headache was markedly diminished at that time. (c) CT image
taken 72 hrs after the initiation of high-dose dexamethasone therapy. Tumor enhancement is no
longer evident and edema fluid continues to resolve. The patient had no residual headache and was
neurologically normal at the time of this scan. The tumor was successfully removed without event
on the following day. It has been three decades since the initial recognition of dexamethasone's
efficacy in the setting ofperitumoral brain edema. Recent studies have at once suggested arole for
VPF in tumoredemagenesis, and amechanism fordexamethasone efficacy by its inhibitory actions
on VPFexpression and activity.
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brain tumor surgery are more likely to have a better surgical outcome if their neurologic
deficits are minimized preoperatively. The clinical efficacy of dexamethasone therapy
correlates with a partial resolution of vasogenic brain edema and a reduction in tumor
enhancement evident on CT studies (Figure 3). Experimental studies indicate that this
relates to a retardation in vascular extravasation and edema fluid formation. Notably, the
clinical responsiveness of brain edema to dexamethasone has been shown to correlate
with cytosolic glucocorticoid-receptor concentrations in several types of intracranial
tumor. The clinical use ofhigh-dose dexamethasone as an adjunct to brain tumor therapy
now spans three decades. Nevertheless, the pharmacological basis for this remarkable
clinical, physiological, and radiographic response remains open to conjecture, and the
rationale for glucocorticoid use in this setting remains largely empirical. It follows that
further study ofthe mechanism, and specificity ofdexamethasone's actions in the setting
ofneoplastic brain edema, would be worthwhile as it might reveal novel insight into the
very mechanism by which brain edema evolves, as well as suggestalternative therapeutic
avenues.
THE BLOOD-BRAIN AND BLOOD-CSF BARRIERS DEFINED
Paul Ehrlich, a 19th century bacteriologist, first noted that intravascular injection of
vital dyes stained all organs except the brain. His interpretation, that this related to a dif-
ferential organ affinity for the dye was later proven incorrect when in 1913 a student of
his, Edwin E. Goldmann, showed that injection oftrypan blue into the cerebrospinal fluid
readily stained the brain but failed to enter the bloodstream. The BBB is now recognized
to be a complex, highly selective anatomical and physiological barrier, which regulates
the entry andegress ofcerebral nutrients and biological substances essential for the main-
tenance of cerebral metabolism and neuronal activity [15-17]. Although Goldmann was
first topostulate thatbrain capillaries were the anatomic basis for the blood-brain barrier,
direct confimation did not occur until the 1960's when electron microscopy was used to
demonstrate the occurrence ofcontinuous pentalaminar tightjunctions between adjoining
endothelial cells. In an elegantly designed series of experiments, Thomas S. Reese and
Morris J. Karnovsky at the Harvard Medical School, andReese and Milton W. Brightman
at the National Institutes of Health, demonstrated the inability of an electron-dense
macromolecular marker (horseradish peroxidase) to pass from either the intravascular or
interstitial compartments respectively, through the interendothelial tight junctions [18,
19].
Endothelial cells ofthe cerebral vasculature display several features attesting to their
unique participation in blood-brain barrier function (Table 3). The single most important
feature is the high-resistance pentalaminar tight junction that fuses endothelial cells
together in a continuous layer, and effectively forms a physical barrier between circulat-
ing molecules andcells, and the cerebral interstitial space. Additional specialized features
include continuous capillary basement membranes, a paucity ofendothelial micropinocy-
totic activity, an abundance of endothelial cell mitochondria, the absence of endothelial
Table 3. Ultrastructural features of blood-brain barrier microvessels.
Endothelial cell pentalaminar tightjunctions
Continuous capillary basementmembranes
Paucity ofendothelial cell micropinocytotic activity
Abundanceofendothelial cell mitochondria
Absence ofendothelial cell membrane fenestrations
Investiture ofcapillary basementmembrane by astroglial footprocesses
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membrane fenestrations, and complete investiture by astroglial foot processes (Figure 4)
[17-24]. Therefore, virtually all macromolecules are excluded by theblood-brain barrier,
and passive diffusion of substances into the brain largely depends upon their physical
characteristics such as molecular size, electrostatic charge, and lipophilicity. Lipid solu-
bility, as quantitated by an oil-water partition coefficient, is the most important chemical
property determining a substance's ability to penetrate the blood-brain barrier. Amino
acids, glucose, biogenic amines and other essential brain nutrients may gain entry by a
complex system of membrane transporters. A variety of molecular entry mechanisms
exist including active transport (energy-requiring), facilitated transport (not energy-
requiring), and enzymatic modification of a molecule prior to entry. The blood-cere-
brospinal fluid barrier is an analagous but distinct entity whose function is governed by
the selective secretory activity of the choroid plexus epithelium. Together, the blood-
brain and blood-CSF barriers regulate the composition of the cerebral interstitial fluid
and cerebrospinal fluid within well-defined limits. Disturbances in any of the compo-
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Figure 4. Artistic interpretation depicting the normal cytoarchitectural relationships between
a blood-brain barrier microvessel and the surrounding glial cells (astrocytes). The critical com-
ponent of this permeability barrier occurs at the interendothelial cell junction (pentalaminar tight
junction). Intimate intercellular contacts and chemical signalling are believed responsible for the
highly specialized features expressed by these microvessels under normal circumstances (Type A
morphology).
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nents of the blood-brain or blood-cerebrospinal fluid barriers, if significant, will result in
cerebral edema.
PATHOPHYSIOLOGY AND CLASSIFICATION OF BRAIN EDEMA
Brain edema is generally defined as a condition whereby disturbed cerebral homeo-
static mechanisms result in an abnormal increase in brain tissue volume that is lagely
attributable to an increase in water content. Many pathological processes are known to
result in brain edema formation. Although the pathophysiological mechanisms are not
completely understood, it is apparent that several distinct varieties of cerebral edema
exist [12, 15, 25]. Vasogenic brain edema (Type 1) is associated with marked alterations
of cerebral microvascular elements. This disturbance in the blood-brain barrier results in
extravasation of plasma-like fluid into the white matter interstitial space (white matter
edema). Alternatively, edema fluid may become sequestered into a single loculated cavity
or cyst. Diffuse vasogenic edema is seen clinically in the setting ofbrain tumor, abscess,
intracerebral hemorrhage, malignant systemic hypertension, and after prolonged seizure
activity. Cyst formation is seen exclusively in the setting ofcertain neoplasms. Cytotoxic
brain edema (Type II) occurs when direct damage to cortical cells causes impaired cellu-
lar membrane homeostasis and increased permeability. Intracellular accumulation of
sodium and water results in cellular swelling (gray matter edema) at the expense of the
interstitial space. Cytotoxic brain edema is seen clinically in the setting of cerebral
anoxia, ischemia or infarction, diabetic coma, hepatic encephalopathy, Reye's syndrome,
and pseudotumor cerebri. Interstitial brain edema (Type III) refers to an infiltration of
CSF from the ventricular cavities into the periventricular white matter. Cerebral intersti-
tial fluid normally communicates freely with the ventricular cavities and bulk diffusion
into them occurs in a centripetal fashion. Interstitial brain edema occurs in the setting of
acute hydrocephalus wherein CSF under increased pressure is forced to flow centrifugal-
ly across the ependymal surface lining the ventricular cavities, and into white matter
interstitial space. Blood-brain barrier function is nottherefore altered. Osmotic/hydrostat-
ic brain edema (Type IV) occurs when a sudden disturbance in Starling's equilibrium
results in the development of an osmotic gradient between plasma and cerebral tissue.
Initially, the edema consists largely of free water without electrolytes or plasma proteins.
The brain eventually looses electrolytes without gaining significant quantities of water.
Clinical impairment is more likely related to cellularpotassium loss and hyponatremia, as
elevated intracranial pressure is nota consistent association. Osmotic or hydrostatic brain
edema occurs with primary water intoxication, rapid hemodialysis, and the inappropriate
secretion ofantidiuretic hormone (SIADH).
This classification of cerebral edema is quite sound and clinically useful provided
one recognizes its limitations. It is well recognized that disparate types of brain edema
may coexist. For example, vasogenic and cytotoxic edema can occur together in certain
settings depending upon the nature and severity of the initial insult. Furthermore, if one
considers the variety ofdistinct pathological events that result in expression of the same
pattern of edema, a lack of pathophysiological specificity becomes self-evident.
Nevertheless, this template rightfully remains the standard for all further discussion
regarding edema ultrastructure, pathology, andphysiology.
BRAIN TUMORS AND NEOPLASTIC BRAIN EDEMA
The clinical andpathologicalspectrum ofhuman brain tumors
Tumors of the central nervous system pose a major challenge to the field of oncol-
ogy. Intracranial neoplasms account for 2% ofall cancer-related deaths. They continue to
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be associated with a high degree of morbidity and mortality, despite advances in neuro-
surgery, radiotherapy, and chemotherapy [26-34]. Primary tumors of the central nervous
system account for approximately 10% of all malignancy. Furthermore, cancer is second
only to trauma as a cause of death in childhood, and brain tumors represent the second
most common childhood malignancy. About 20,000 new primary brain tumors and an
additional 20,000 secondary or metastatic brain tumors are diagnosed each year in the
United States.
Approximately 40% ofallcentral nervous system tumors are primary tumors derived
from neuroectodermal supporting cells (glial cells) such as astrocytes, oligodendrocytes,
and ependymal cells. Astrocytomas comprise 60 to 70% of glial cell tumors (gliomas).
Several attempts havebeen made to create apractical grading system for these lesions by
correlating histological features with their biological behavior. One of the more
commonly employed systems assigns a numerical grade from I through IV. Grade I
(benign astrocytoma) and Grade II (cellular astrocytomas) lesions are both generally con-
sidered histologically andbiologically benign tumorscharacterizedby variabledegreesof
hypercellularity, and relatively prolonged survival after treatment with surgical excision
orradiation therapy. Grade III (anaplastic astrocytoma) and Grade IV (glioblastoma mul-
tiforme) astrocytomas display malignant cellular features such as extreme hypercellulari-
ty, pleomorphism, increased nucleocytoplasmic ratio, mitotic figures, nuclear hyperchro-
matism, multinucleation, and bizarre giantcell forms. Malignant stromal changes such as
necrosis, pseudopalisading, edema fluid accumulation, intravascular thrombosis, hyper-
vascularity, and microvascular endothelial proliferation, occur almost exclusively in the
most highly malignant tumor varieties (glioblastoma multiforme).
Survival in patients with malignant gliomas is poor and ranges from 3 to 6 months
untreated. Therapy with dexamethasone alone may only extend survival by several
months at most. Combined surgical excision, radiation, and chemotherapy significantly
improve survival but mortality still approaches 95 to 100% at 5 years post-diagnosis. A
peculiarity ofprimary brain tumors is the rarity with which they metastasize beyond the
central nervous system. Exceptions to this behavior are well documented in the literature
and most commonly occur with medulloblastoma and glioblastoma multiforme.
Nevertheless, in most instances, malignant brain tumors are locally invasive, and there-
fore, limit their growth to the fixed confines of the intracranial cavity. Clinically signifi-
cant recurrences after surgical excision and radiation therapy are most likely to occur at
the siteoftheoriginal tumor(>95% ofgliomasrecurwithin 2 cm oftheoriginal resection
margin). Certain tumors demonstrate a predilection for seeding malignant cells into the
subarachnoid space throughout the leptomeninges and spinal cord along CSF pathways
(primitive neuroectodermal tumor, medulloblastoma, ependymoma, pineoblastoma,
ependymoblastoma). This behavior has also been reported foranaplastic astrocytoma and
glioblastoma multiforme when these lesions have anatomical access to the subarachnoid
space. Extension, spread, and dissemination ofa brain tumor in any of the latter fashions
would naturally pose additional diagnostic and therapeutic challenges.
Brain tumors most likely to be associated with clinical and CT-evident vasogenic
cerebral edema include most primary malignant tumors (anaplastic astrocytoma and
glioblastoma multiforme), many secondary malignant tumors (metastases from lung,
breast, renal, thyroid, and colon cancer, and malignant melanoma), and certain benign
tumors (meningioma). In addition, fluid-filled macrocysts are frequently seen in associa-
tion with benign astrocytomas and hemangioblastomas, and likely represent a distinct
epiphenomeneon of vascular extravasation. Management of brain tumors is complicated
by the presence of peritumoral edema, which frequently limits a patient's tolerance for
essential therapies (surgery, radiotherapy, and chemotherapy), and which may,
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themselves, initially contribute to cerebral swelling. Furthermore, the risk of a poor out-
come after neurosurgical excision ofabrain tumor is increased substantially in the setting
ofsevere, symptomatic brain edema. For these reasons, an expanded understanding ofthe
pathophysiology of peritumoral brain edema is essential to the effective management of
patients with intracranial tumors.
Ultrastructure ofthe tumormicrovasculature andvasogenic brain edema
Prior reports have described the increased permeability characteristic of the
microvasculature within primary and metastatic malignant brain tumors, as well as cer-
tain benign tumors [35-37]. The attention ofinitial studies primarily focused on the mor-
phology of cerebral edema, and the altered vascular ultrastructure of intrinsic tumor and
peritumoral blood vessels. Vasogenic brain edema (VBE) was characterized by infitra-
tion of the white matter interstitial spaces by an ultrafiltrate ofplasma (water, salts, pro-
tein) [12, 15, 16, 25]. It has been postulated that the specialized features ofnormal brain
endothelial cells result from cellular contact with normal brain tissues (basement mem-
brane, pericytes, interstitial stroma, astrocytes) [20, 21, 35-37]. The latter consists largely
ofastrocytes, whose cytoplasmic processes completely invest these microvessels (Table 4
and Figure 5a). It would therefore follow that the vastly altered milieu inherent in brain
tumors, where microvessels develop amongst a varying mixture ofnormal and abnormal
astrocytes (low-grade gliomas) (Table 4 and Figure Sb), or in the presence of either
markedly degenerate astrocytes (high-grade gliomas) or completely in the absence of
astrocytes (metastatic tumors) (Table4 and Figure 5 c), mightaccount for adedifferentia-
tion ofbrain endothelial cells into a less specialized phenotype (i.e., not expressing tight
junctional architecture). One can further speculate that microvessels growing into mini-
mally altered environments mightretain some anatomical and functional blood-brain bar-
rier features as seen in low-grade astrocytomas associated with minimal or no brain ede-
ma (Figure 6). In contradistinction, the microvasculature ofhighly anaplastic gliomas and
brain metastases retains little or no semblance to normal blood-brain barrier microvessels
(associated with extensive brain edema) (Figure 7).
Statement ofworking hypothesis
Several features oftumor-associated vascular endothelium, such as widened intercel-
lular junctions, discontinuous tight junctions, membrane fenestrations, noncontiguous
basement membranes, active micropinocytosis, and paucity of mitochondria, contrast
sharply with the normal architecture of the blood-brain barrier (Table 5 and Figures 4, 6
Table 4. Proposed functional and morphological classification ofbrain microvessels.
Microvessel Type Departure from Tumor Differentiation/ Vascular VPF
Barrier Vessels Type Extravasation Expression
Type A Morphology none normal glia (notumor) none none
(Figures 4 and Sa) normal brain
Type B Morphology moderate low grade (partially minimal or present
(Figures Sb and 6) differentiated cyst formation
solid orcystic astrocytoma
Type C Morphology extensive high grade (undifferentiated) extensive edema present
(Figures Sc and 7) anaplastic astrocytoma formation
glioblastoma multiforme
metastatic tumor
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Figure 5. Artistic interpretation of the three dimensional relationships between microvessels,
normal astrocytes, less differentiated neoplastic astrocytes, and undifferentiated tumor cells.
(a) Normal cellular interactions confer a typical pattern to the brain microvascular bed (Type A
morphology). (b) Partial replacement of the astrocytes by less differentiated neoplastic glial cells is
thought to result in disturbed cellular contacts andperturbations ofchemical signaling. Type B mor-
phology is observed with certain low grade gliomas. Vascular extravasation is less consistent in this
setting but may be expressed as variable degrees of contrast enhancement, edema formation, or
tumor cyst formation. (c) Ultimately, extreme degrees of departure from the normal microvascular
architecture occur in the setting of highly malignant astrocytic and metastatic brain tumors. This
figure depicts a vascular bed that is markedly altered by both the absence of normal cellular con-
tacts as well as the influence of chemical signalling by tumor angiogenesis factors (Type C mor-
phology). In this instance the stage is set for permeability induction by chemical mediators such as
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Figure 6. Artistic interpretation depicting a slightly atypical microvascular architecture In
response to the altered environment imposed by the replacement of normal glial cells with
low-grade (partially degenerate) neoplastic astrocytes. One can speculate that microvessels
growing into minimally altered environments might retain some anatomical and fimctional blood-
brain barrier features (Type B morphology). Tumors retaining this architecture are associated with
minimal brain edema and tumor enhancement. Tumor-associated cyst formation, an epiphe-
nomenon ofvascular extravasation, may occur ifVPF is expressed by these lesions.
and 7) [16-19, 35-43]. However, many of these heterotypical cellular features of brain
tumor microvessels actually typify the endothelium lining the otherwise normal peripher-
al vasculature (not involving the blood-brain barrier). While the peripheral vasculature is
not inherently permeable to macromolecules, it does appear to be exquisitely sensitive to
vascular permeability induction (VPI) by physiologically occurring substances such as
histamine, bradykinin, serotonin, and prostaglandin [44-47]. Notably, the normal cerebral
blood vessels appear totally unable to respond to these potent mediators ofmicrovascular
extravasation.
It now appears unlikely that the absence of continuous pentalaminar tight junctions
would solely account for the abnormal permeability of brain tumor microvessels.
Nevertheless, alteration of this critical component of the blood-brain barrier may at once
render brain tumor microvessels similar to the peripheral microvasculature in anatomical
form, and physiological reactivity to a variety of permeability-inducing substances.
Recent studies have suggested tumor-induced permeability induction to be linked to a
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Figure 7. Artistic interpretation depicting the highly degenerate microvascular architecture
observed in the complete absence of normal glial-endothelial cell contacts. Normal glial cells
are completely replaced by undifferentiated tumor cells derived from astrocytes, or systemic can-
cers that have metastasized to the brain. The microvasculature of highly anaplastic gliomas and
brain metastases retains little or no semblance to normal blood-brain barrier microvessels (Type C
morphology). These tumors are commonly associated with extensive brain edema and tumor
enhancement. Immunohistochemical evidence ofVPFexpression by theselesions hasrecently been
demonstrated.
cellular cascade entailing: tumor-derived VPF-CMR binding, a rapid and transient eleva-
tion in endothelial cytosolic calcium [Ca++li, reduction in cellular F-actin content [FA]i,
and endothelial cytoarchitectural distortion (ECD) culminating in retraction of the
interendothelial junctions and consequent extravasation of water and macromolecules
through the widened interendothelial clefts. It is believed that all endothelial cells
(including BBB endothelium), are capable of responding to the initial steps of the cas-
cade. It is therefore postulated that the lack of VPF-CMR induced extravasation in BBB
endothelium reflects aphysical inability to open intercellular clefts and that this physical
constraint reflects thatimposed by the pentalaminarjunctional structure. Therefore, itfol-
lows that in tumormicrovessels notexpressing BBB architecture:
VPF+ CMR + [Ca++]i- [FA]i -----> ECD + VPI ----->VBE.
This gross oversimplification of the mechanism ofpermeability induction retains its
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Table 5. Ultrastructural features ofbrain tumor microvessels.
Widened interendothelialjunctions
Discontinuous endothelial cell tightjunctions
Endothelial cell membrane fenestration
Noncontiguous basement membranes
Abundant endothelial cell micropinocytosis
Paucity ofendothelial cell mitochondria
Table 6. Acute management ofperitumoral brain edema.
Surgical cytoreduction (tumor excision)
Fluidrestriction
Diuresis (furosemide andmannitol)
High-dose intravenous dexamethasone
Ventricular CSF drainage
utility as a template for further investigative efforts. The background and ongoing
research seminal to this hypothesis is thoroughly discussed throughout the remainder of
this work.
Clinical approach andmanagement ofperitumoral brain edema
Patients with brain tumors frequently present with clinical manifestations ofelevated
intracranial pressure. They typically complain ofheadache, nausea, vomiting, drowsiness
and double vision. Seizures and focal neurologic deficits are also commonly present, and
their precise pattern, distribution, and severity is dictated largely by the location and size
of the tumor and the extent of the surrounding cerebral edema. Progressive elevation of
the intracranial pressure will result in further clinical deterioration to lethargy, stupor, and
coma. Ultimately, intracranial hypertension leads to cerebral herniation with consequent
fatal brain stem compression. In this regard, peritumoral vasogenic cerebral edema
deserves reemphasis as a frequent and important accompaniment of intracranial tumors.
The combined effects ofrapid tumor growth and cerebral swelling within the confines of
the rigid (fixed volume) cranial vault, dictate the rapidly progressive clinical decline
observed in patients with malignant brain tumors. Methods of acutely managing these
patients include tumor excision (surgical cytoreduction), fluid restriction, diuresis with
intravenous furosemide and mannitol, high-dose intravenous dexamethasone, and ventric-
ular CSF drainage (Table 6). Tumor excision addresses the tumor mass and its vascular
bed directly, and as a consequence, eliminates the source ofvasogenic edema fluid. Fluid
restriction and diuretics decrease intracranial pressure by contracting the intravascular
space and facilitating the egress of edema fluid from the cerebral interstitial space and
into the vascular compartment. Furosemide is thought to act additionally by curtailing
CSF production through its inhibitory action carbonic anhydrase, an enzyme key to CSF
production. Ventricular CSF drainage lowers intracranial pressure both by reducing the
volume of the cranial contents, and by facilitating the egress ofedema fluid centrifugally
into the ventricular system. Therapeutic CSF drainage is most efficacious in the specific
setting ofhydrocephalus related to a tumor obstructing CSF outflow. However, in the set-
ting of a focal mass lesion with impending brain herniation, CSF decompression may be
contraindicated as it may hasten the shift intracranial contents, thus facilitating hernia-
tion.
Glucocorticoids such as dexamethasone are remarkably effective in reducing the
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neurological deficits and intracranial hypertension associated with malignant brain
tumors [11, 48-50]. Their efficacy is not the result of tumor cytoreduction as in vivo and
in vitro studies have failed to demonstrateanycytolytic actionofsteroids onbrain tumors
in general, and primary glial tumors in particular. However, the cytolytic action ofgluco-
corticoids on peripheral lymphoid tumors is well described and does have a CNS corre-
late with primary and secondary CNS lymphomas. Nevertheless, the latter instances are
exceptionally rare and a substantial body ofCT data clearly indicate a direct action upon
the peritumoral edema [51-54]. Moreover, myriad studies have clearly shown neoplastic
vasogenic brain edema to be the only type ofbrain edema thatresponds clinically to glu-
cocorticoid therapy [55-59]. Once a patient has been stabilized with dexamethasone, the
brain tumor may be more safely neurosurgically excised. The need foradditional therapy
postoperatively is largely governedby the extentoftumorresection andhistopathological
diagnosis. Definitive treatment plans are proposed only after consultation between the
neurosurgeon, neurologist, medical oncologist, and radiation therapist. Regretably, it is
not unusual forpatients with residual tumorandedema (i.e., those in greatest needoffur-
ther therapy) to haveadjunctiveradiation orchemotherapy interrupted as a resultofexac-
erbation of the edemagenic component. Once again, dexamethasone, employed in doses
yet higher than those used initially, may control the brain edema sufficiently to allow
adjunctivetherapy to resume.
MEDIATORS OF MICROVASCULAR PERMEABILITY: AN OVERVIEW
Introduction: Classicalandnovelmediators ofmicrovascularpermeability
The microvasculature of many solid tumors exhibits increased permeability in com-
parison with normal tissues. Certain pathological reactions associated with neoplastic
growth are likely to resultfrom permeability induction by tumor cells. Clinical manifesta-
tions ofthis process include decreased total serum albumin, production ofmalignanteffu-
sions and ascites, soft tissue edema, and paraneoplastic arthropathy [60-65]. Neoplastic
vasogenic brain edema derives from a physiological alteration in the blood-brain barrier
that is manifested by ultrastructural changes in tumor microvessels, and the extravasation
of water, salts, and serum proteins into the peritumoral white matter [12, 16, 35-37].
Several biochemical mediators have been implicated in the pathogenesis ofbrain edema.
Substances such as histamine, serotonin, bradykinin, glutamic acid, polyamines,
leukokinins, lymphokines, prostaglandins, thromboxane, prostacyclin, kallidin, lympho-
cyte permeability factors, kallikrein, interleukin-2 (IL-2), and plasminogen activator, are
potent inducers of microvascular permeability associated with a variety of allergic, trau-
matic, ischemic, infectious, and inflammatory conditions [44, 63-77]. Furthermore, atten-
tion has recently been focused on the potential role ofoxygen free radicals in the forma-
tion oftraumatic andperitumoral brain edema (Table 7) [78,79].
Initialstudies oftumor-derived vascularpermeabilityfactors
A series ofproteinaceous VPFs have stirred considerable interest in the past several
years [60-65, 72, 74, 76, 80-94]. The existence ofVPF was firstrecognized when guinea
pig line 10 hepatocarcinoma cells promoted the accumulation of ascites fluid after
intraperitoneal implantation [60]. This factor (gVPF) was found to be a 34 to 42 kDa
basic protein with a strong affinity for immobilized heparin and a permeability-inducing
potential three orders ofmagnitude greater than histamine. The presence ofgVPFactivity
has been routinely determined by the Miles assay, a quantitative bioassay for induction of
microvascular permeability [451. Investigators found that gVPF-induced microvascular
extravasation was rapid in onset (1 min) and of short duration (20 min), suggesting a
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Table 7. Potent mediators ofmicrovascular permeability.
Histamine
Serotonin
Bradykinin
Leukotrienes
Prostaglandins
Lymphokines
Kallikreins
Interleukin-2
Oxygen freeradicals
VPF/VEGF
direct action upon the microvascular endothelial cell. Furthermore, gVPF activity
induced a period ofdesensitization wherein microvessels previously exposed to this sub-
stance became temporarily refractory (20 or 30 min) to permeability induction by further
gVPF perturbation. Light and electron microscopy showed that gVPF did not induce
endothelial cell damage, mast cell degranulation, or an inflammatory cell inflltrate when
injected into the guinea pig subcutaneous microvasculature. Moreover, intravascular
injection of colloidal carbon resulted in the labeling of diaphragmatic, mesenteric, peri-
toneal, and gastrointestinal serosal post-capillary venules, thus supporting an action of
gVPF upon these critical microvessels [70, 71, 95]. Rabbit-derived immunoglobulin
(polyclonal IgG) raised to partially purified guinea pig hepatocarcinoma-derived gVPF
neutralized essentially all permeability-inducing activity present in tumor ascites fluid
and conditioned medium from line 10 cell cultures. This antibody also blocked the
ascites formation that follows intraperitoneal injection ofline 10 tumor cells. In addition,
VPF activity from guinea pig line 104 Cl fibrosarcoma and Walker rat carcinoma lines
was similarly inactivated by anti-gVPF antibody. It was suggested that secretion of VPF
may be a common feature of tumor cells accounting for the abnormal accumulation of
fluid associated with neoplasms [60, 61].
Soon thereafter, a tumor-derived capillary endothelial cell growth factor was identi-
fied andpurified from ratchondrosarcoma extracellular matrix [96]. This 18 kDacationic
polypeptide had a marked affinity for heparin, and therefore differed from PDGF and
EGF. Nanogram quantities of this substance stimulated both proliferation and mobiliza-
tion of capillary endothelial cells in culture, activities thought to be key components of
angiogenesis induction. Other studies showed that while heparin potentiated tumor-
induced angiogenesis on the chorioallantoic membrane, angiogenesis was inhibited when
both heparin and cortisone were administered simultaneously. Thus, glucocorticoids were
once again identified as having an inhibitory action on a specific process essential to the
biology oftumor growth and metastasis [97, 98]. At this point, investigators interested in
factors acting directly upon endothelial cells diverged into two groups: those studying
tumor angiogenesis factors (TAFs) and other endothelial, fibroblast, and smooth muscle
cell mitogens, and those investigators studying VPFs [60-65, 80, 83-86]. Interest in
these heparin-binding molecules has only recently reconverged with the publication of
the amino acid sequence of a VPF molecule (vascular endothelial growth factor or
VEGF) exhibiting both permeability-inducing andangiogenic mitogen capabilities (Table
8) [80-82, 87-93, 97, 98].
Partial purification and characterization of VPF from a human HT-29 colon adeno-
carcinoma cell line conditioned medium showed it to be a 45 kDa acidic protein which
lacked a specific binding affinity for heparin [65]. Like guinea pig hepatocarcinoma
gVPF, HT-29 permeability-inducing activity was not inhibited by antihistamines (H1 or
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Table 8. VPF/VEGF action/activity in vitro.
Physiological Action/Activity Assay Performed/Method References Cited
Microvascular penneability Miles assay 60, 80, 82, 83, 85,86
125I-albumin extravasation
Endothelial calcium transients fluorescence spectrophotometry 84
fura-2/AM calcium ionprobe
Endothelial cellmigration chickchorioallantoic membrane 81, 91,93, 152, 153
nude mouse subrenal capsule
visual inspection/scoring
Endothelial cellreplication endothelial cell culture 81, 91,93
cell counts after VPF incubation
Coulter counter
3H-thymidine incorporation
Endothelial cellbinding affinity 125I-VPF/cellular cross-linking 125-128
quantitative autoradiography
H2 receptor blockade), antikinins, pepstatin A, or indomethacin. Several other human
tumor lines have since been tested for VPF activity. One study demonstrated significant
VPF expression by human osteogenic sarcoma, bladder carcinoma, cervical carcinoma,
and fibrosarcoma. VPF activity from these tumors comigrated closely with guinea pig
line 10 gVPF (34 to 42 kDa) and was neutralized by antibodies raised to line 10 gVPF.
Furthermore, the VPF expressed by two human tumorigenic cell lines was also character-
ized by heparin affinity and an apparent size of38 kDa [62]. Demonstration ofthe highly
conserved nature of VPF molecules across species lines suggested a broader purpose for
VPF-mediated permeability induction by tumors (i.e., extravasation of nutrients to sup-
port tumor growth in the extracellular matrix) [62, 97, 98]. Studies comparing VPF pro-
duction by matched pairs of nontumorigenic and tumorigenic cell lines showed tumori-
genic cell lines to secrete at least 14-fold more VPF activity, thus lending further support
for a specific role ofVPF and enhanced microvascular permeability in tumorbiology and
growth [62].
Identification ofhuman brain tumor vascularpermeabilityfactor
Serum-free conditioned media derived from cultures of primary human malignant
brain tumors (anaplastic astrocytoma and glioblastoma multiforme) have been shown to
contain a factor that induces microvascular extravasation offluid andprotein in the Miles
permeability bioassay [80]. VPF activity was not expressed by cultured human fibrob-
lasts, meningioma cells, or several lines of low-grade astrocytomas (gliomas not usually
associated with CT-evidentbrain edema), however itwas strongly expressed by anumber
ofrapidly-growing malignant gliomas (associated with CT-evident edema). Furthermore,
fluid derived from the cysts associated gliomas was shown to contain potent VPFactivity.
HG-VPF appears to differ from commonly recognized mediators of vascular permeabili-
ty. Early studies did, however, demonstrate several similarities to guineapig line 10hepa-
tocarcinoma-derived gVPF. HG-VPF is a 41 to 56 kDa basic cationic polypeptide which
avidly binds heparin [83, 84]. Like gVPF, the time course of permeability induction by
HG-VPF is rapid and transient suggesting a direct action upon endothelial cells. As in
previous gVPF studies, prior exposure to HG-VPF results in a period of refractoriness,
during which further induction of microvascular extravasation by HG-VPF does not
occur. Expression of HG-VPF activity is inhibited by incubation of glioma cell cultures
with cycloheximide or dexamethasone. Finally, a rabbit-derived polyclonal IgG raised to
gVPF completely inactivated HG-VPF activity in partially purified conditioned media
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(U251 human malignant glioma), thus further supporting homology between these sub-
stances (polyclonal anti-VPF IgG was kindly provided by Donald. R. Senger,Ph.D., Beth
Israel Hospital, Harvard Medical School, Boston) [80].
In order to eliminate variations in HG-VPF expression associated with use ofseveral
different tumor lines, serum-free conditioned medium derived from low-passage cultures
ofasingle cloned human malignantglioma line (U251) wereemployed forall subsequent
HG-VPF studies. A partially purified U251 glioma protein product containing HG-VPF,
has been shown to induce rapid and reversible elevations in cytosolic calcium in several
types of cultured endothelial cells [83-85]. The HG-VPF induced intracellular calcium
ion changes exhibited dose-responsiveness and were inhibited by nonspecific calcium
channel blockers (lithium, cobalt, manganese, and lanthanum ions) suggesting that influx
of extracellular calcium ions was responsible for the observed cytosolic calcium tran-
sients. Re-exposure ofendothelial cells to the HG-VPF stimulus failed to produce a sec-
ond calcium ion transient increase suggesting that a period of refractoriness similar to
that observed in vivo, had been induced by the initial HG-VPF exposure. Most signifi-
cantly, HG-VPF induced calcium changes were completely inhibited in endothelial cells
previously exposed to dexamethasone, thus suggesting a second explanation for its
clincial efficacy.
IITIAL BIOCHEMICAL AND PHYSIOLOGICAL STUDIES OF HUMAN
BRAIN TUMOR VPF
HG-VPF activity, expression, andbehaviorin apermeabilitybioassay
Serum-free conditioned medium from low-passage confluent monolayercell cultures
of human malignantastrocytoma lines evoked macromolecular extravasation (quantitated
by measurement of 125I-BSA accumulation) in the Miles cutaneous microvascularperme-
ability assay [80]. Intradermal injection of this factor results in a permeability change
with a rapid onset at 1 to 5 min, a peak at 5 to 15 min, and reversibility by 20 to 30 min.
In addition, there is a characteristic period ofdesensitization, refractoriness or tachyphy-
laxis whereby injection of HG-VPF into previously exposed sites results in no further
induction of permeability. Conditioned medium from benign astrocytoma, meningioma,
or fibroblasts demonstrated no significant VPF activity. Fluid aspirated from a cystic
glioblastoma contained very high HG-VPF activity, whereas no activity was evident in
samples ofcerebrospinal fluid from a normal volunteer, apatient with a sacral chordoma,
or a patient with a malignant cerebral glioma. HG-VPF activity increased as the duration
ofculture incubation waslengthened.
Physical andchemical characterization ofhunan glioma-derived VPF
HG-VPF is an acid-stable heat labile 41-56 kDa molecular weight polypeptide,
which is hydrophobic and positively charged under physiological conditions [83]. HG-
VPF activity was abolished by treatment with trypsin or pepsin, but was unaffected by
ribonuclease A, chondroitinase A,B,C, hyaluronidase or lipase. Similarly, HG-VPF activ-
ity is not inhibited by soybean trypsin inhibitor or hexadimethrine (both known antago-
nists of tissue plasminogen activator, Hageman factor, and serum kallikrein), aprotinin
(an antgonist of both plasmin and tissue kallikrein), phenylmethanesulfonyl fluoride (a
serine esterase (elastase) inhibitor), or by pepstatin A (an acid protease inhibitor which
inactivates vascular permeability-inducing leukokinins). Treatment of HG-VPF with
dithiothreitol abolished permeability-inducing activity, indicating the presence ofat least
one essential disulfide bond in this molecule. VPFdisplays a marked affinity for immobi-
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lized heparin (heparin-Sepharose). In addition, we found 90-95% binding of sample
activity to hydrophobic resin (phenyl-Sepharose), and hydroxylapatite. While 40-45% of
HG-VPF activity was bound by negatively charged resin (carboxymethyl-Sepharose),
only 5% of sample activity was bound to positively charged resin (diethylaminoethyl-
Sephacel). The latter resin sequestered 80-85% of sample protein. Employing a heparin-
Sepharose column and a NaCl gradient generator, it was determined that peak elution of
HG-VPF activity occurs at a salt concentration of 0.45 N NaCl. Specific activity was
increased 26-fold by this step. When this partially purified sample was applied to an
HPLC sizing column, HG-VPFactivity eluted in the41-56 kDafraction. Furthermore, an
additional 25-fold increase in specific activity was realized with this step, thus increasing
the total approximate purification to 1,000-fold.
Dexamethasone inhibition ofHG-VPF expression andactivity
Studies to determine how dexamethasone affects HG-VPF expression by cultured
human glioma cells failed to show a direct toxic effect as measured by cell viability
(>98% by trypan blue exclusion), and final cell counts [83]. Although HG-VPF expres-
sion was significantly inhibited by the presence of glucocorticoid, this effect was not
associated with a general inhibition of cellular protein synthesis as determined by 3H-
leucine incorporation. We had previously determined that treatment of test animals with
dexamethasone immediately beforeperforming thepermeability assay did notconferpro-
tection against HG-VPF induced extravasation. Coinjection ofdexamethasone with HG-
VPF also failed to impart a membrane stabilizing protective effect as extravasation was
unhindered. In fact, significant inhibition of HG-VPF activity in vivo only occurred in
test animals given dexamethasone at least 1-2 hrs before performing the permeability
assay. To determine whether the inhibitory action ofdexamethasone was mediated by de
novoprotein synthesis, aseries ofin vivo studies were performed whereby actinomycin D
was administered 2 hrs prior to dexamethasone treatment. In vivo inhibition of HG-VPF
activity by dexamethasone was found to be partially reversed in animals given actino-
mycin D prior to steroid. This suggested that de novo synthesis of a specific polypeptide
intermediate isrequired for theprotective effect ofdexamethasone to occur. These obser-
vations strongly argue against a nonspecific steroid-induced membrane stabilization as
thekeyphysiological event.
HG-VPF induction ofcytosolic calcium ionfluxin endothelial cells
Recent advances in our understanding of endothelial cell growth requirements have
allowed their routine culture for investigational purposes [19-21, 24, 99-110].
Endothelial cells derived from brain capillaries have received considerable attention
because oftheir unique barrier characteristics [20, 21]. Cytosolic free Ca2+plays apivotal
role in endothelial cytoskeletal alterations and subsequent microvascular extravasation
[84-86, 111-120]. Studies of cytosolic calcium changes have been greatly facilitated by
the development of a series of novel fluorescent calcium ion probes (quin-2/AM, indo-
2/AM, fura-2/AM, fura-3/AM) possessing molecular structures similar to EGTA [113,
117]. They differ from EGTA in that they contain aromatic rings capable ofelectrostatic
interactions with the functional groups that participate in the chelation of free cytosolic
calcium ions [Ca2+]i. Chelation ofdivalent cations changes the fluorescence and ultravio-
let light-absorption properties of these molecules. Alterations in fluorescence are in turn
detected and quantitated by a spectrofluorometer. Fura-2/AM has provenparticularly use-
ful with its high sensitivity and specificity for calcium ions. Because of its lipophilicity,
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fura-2/AM is rapidly internalized by endothelial cells. Once internalized however,
deesterification of the acetoxy-methyl group (fura-2/AM ---> fura-2) converts it to a
lipophobic free acid, with only minimal capability for diffusion out ofthe cell. Cytosolic
calcium ion changes in the nanomolar range arereadily detectable with this probe.
Partially purified HG-VPF has been shown to induce significant calcium ion tran-
sients in several varieties ofendothelial cells sustained in monolayer cultures [84]. It did
not, however, elicit a calcium response in two non-endothelial cell lines ([J251 glioma
and fibroblasts). The endothelial cytosolic calcium changes were typically rapid or only
slightly delayed in onset (15-45 sec), and varied in magnitude depending upon the cell
typebeing studied. The largest responses were observed in human endothelial cells. Ithas
already been postulated that such variations may relate to some degree of molecular
species-specificity despite the highly conserved nature of VPF activity [61]. Peak HG-
VPF induced intracellular calcium ion elevations were observed within 60 sec, exhibited
a dose-response phenomenon, and were followed by a sustained elevation above baseline
for 5 to 10 min thereafter. In contrast, exposure of the endothelial cells to the flow-
through product of HG-VPF containing glioma conditioned medium after binding of all
HG-VPF activity to a heparin-Sepharose affinity column, did not produce a change in
intracellular calcium. The brief time course of the HG-VPF induced cytosolic calcium
changes in vitro are compatible with the in vivo kinetics, and is supported by other data
showing prolonged stimulus-response coupling to occur after only transient intracellular
calcium elevations [115].
Exposure ofendothelial cell suspensions to elevated extracellular potassium chloride
(120 mM KCI) failed to induce cytosolic calcium transients. Furthermore, verapamil
(10 gM) failed to inhibit HG-VPF induced calcium changes. These data suggests that
HG-VPF increases cytosolic calcium by a route other than verapamil-sensitive voltage-
gated calcium channels. Addition of2 mM lithium, cobalt, manganese, orlanthanum ions
inhibited HG-VPF induced calcium transients, as did the absence ofextracellular calcium
after chelation with EGTA. This indicates that HG-VPF induced calcium ion changes are
largely dependent upon the influx of extracellular calcium [Ca2+]0 through membraneous
calcium channels. Finally, incubation of endothelial cells for 2 hrs with 10 j±M dexam-
ethasone before exposure to HG-VPF containing medium resulted in inhibition of the
HG-VPF induced cytosolic calcium changes. This inhibition was not observed in similar-
ly treated cells exposed to ATP, nor did it occur when cells were incubated with dexam-
ethasone forless than 1 hr, suggesting the steroid-induced inhibition was specific forHG-
VPF induced calcium flux, and that dexamethasone may mediate its effect through an
intermediary requiring de novo synthesis.
Like VPF, another polycationic substance (protamine), known to induce changes in
vascular permeability, was also shown to induce physiologically significant perturbations
in endothelial intracellular calcium when present in concentrations as low as 10 gg/ml
[121-123]. Induction of calcium release by protamine was rapid in onset, peaked within
30 seconds, and sustained a level above baseline for several minutes thereafter. The pres-
ence ofextracellular divalent cations (2 mM cobalt or manganese) reduced peak [Ca2+]i,
but also more completely affected the post-maximum levels resulting in a rapid downs-
lope and normalization of intracellular calcium. These findings indicated that combined
mobilization of intracellular calcium stores (rapid upslope and peak levels), as well as
influx from the extracellular compartment (peak and sustained levels), are involved in the
response to HG-VPF and protamine. It also suggests that neutralization of the anionic
endothelial cell surface charge imposed by heparin-like moieties, by certain polycationic
substances (VPF, protamine, angiogenesis factors) may play a role in mediating the
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actions ofthese substances. This is supported by ultrastructural evidence that exposure of
renal glomeruli to protamine results in disorganization of the epithelial cell foot process
architecture (podocytes) investing the microvascular glomeruli, and subsequent leakage
of protein into the urine. Endothelial surface charge neutralization by polycations may
simply eliminate theelectrostatic barrier that exists to the vast majority ofproteins (nega-
tively charged), allowing them to escape through pores in fenestratedvessels.
MOLECULAR GENETICS: CHEMICAL AND BIOLOGICAL DEFINITION OF
VPF
Purification andsequencing ofhuman vascularpermeabilityfactor
A VPF has recently been purified to homogeneity from serum-free conditioned
medium of human histiocytic lymphoma cell line U937 [62, 81, 82, 91]. The cDNA
sequence of hVPF was shown to code for a 189-amino acid 38-40 kDa polypeptide with
two identical 20-24 kD subunits that became evident on electrophoresis in reducing gels
(SDS-PAGE). Available data suggests that native hVPF is adimercomposedofdisulfide-
linked subunits, each with the same NH2-terminal amino acid sequence. The NH2-termi-
nal region of the predicted amino acid sequence of U937 hVPF was found to be 78%
identical to the analogous region of line 10 (guinea pig) VPF. The hVPF molecule also
bore some similarities in structure to the ji chain of platelet-derived growth factor
(PDGF-,), as well as several PDGF/v-sis oncogene-related proteins. Similarly, a heparin-
binding VEGF has recently been purified from conditioned media derived from bovine
pituitary folliculostellate cells and phorbol ester-activated human (HL60) promyelocytic
leukemia cells [93]. The cDNA sequence of human VEGF is similar to that of hVPF
except for an additional 24 amino acids in the hVPF sequence. VPFs with similar
immuno-cross reactivity have been detected in conditioned media derived from a variety
of human and rodent tumor cell lines. In addition to its permeability-inducing activity,
hVPF also appears to specifically stimulate endothelial cell growth and angiogenesis
[87-93]. The hVPF molecule did not stimulate [3H]thymidine incorporation or promote
growth of other non-endothelial cell types such as vascular smooth muscle cells (VSM)
or fibroblasts. This featuredistinguished itfrom several otherendothelial cell growth fac-
tors, such as the heparin-binding acidic and basic fibroblast growth factors (FGFs), which
promote growth and replication in non-endothelial, as well as endothelial cell lines.
Conversely, several endothelial cell growth factors including epidermal growth factor
(EGF), fibroblast growth factors (aFGF and bFGF), transforming growth factor (TGF),
interleukin-I (IL1), tumor necrosis factor (TNF), and platelet-derived growth factor
(PDGF) failed to exhibit VPF-like permeability-inducing activity when tested in the
Miles assay. Other studies have confirmed the permeability-inducing activity of IL2,
however this protein bears no size similarity or sequence homology to the hVPF
molecule. 125-hVPF was shown to bind specifically and with high affinity to endothelial
cells in vitro, and could be chemically cross-linked to a high-molecular weight cell sur-
face receptor, thus suggesting a specific site of interaction between hVPF and the vascu-
lar endothelial cell. Complex formation was blocked by excess unlabeled hVPF and anti-
hVPF serum, but not by the addition of excess quantities of the aforementioned growth
factors. Permeability induction in the Miles assay was observed with as little as 1
nanomolar(8 nanograms) hVPF.
The human geneforvascularpermeabilityfactor
In 1991, Tischer et al. showed VSM cells synthesize VEGF mRNA and secrete bio-
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reaction and and cDNA cloning revealed three different forms of the VEGF coding
region as had been reported in HL60 cells. The three forms of human VEGF protein
chain from these coding regions are 189, 165, and 121 amino acids in length. Comparison
of cDNA nucleotide sequences with sequences derived from human VEGF genomic
clones indicates that the VEGF gene is split among eight exons and that the various
VEGF coding region forms arise from this gene by analogous alternative gene splicing:
the 165 amino acid form ofthe protein is missing the residues encoded by exon 6, where-
as the 121 amino acid form is missing theresidues encoded by exons 6 and 7. Analysis of
the VEGF gene promoter region revealed a single major transcription start, which lies
near a cluster of potential Spl factor binding sites. The promoter region also contains
several potential binding sites for the transcription factors AP-1 and AP-2; consistent
with the presence of these sites, Northern blot analysis demonstrated that the level of
VEGF transcripts is elevated in cultured vascular smooth muscle cells after treatment
with the phorbol ester, 12-O-tetradecanoyl-phorbol-13-acetate.
The finding that cultured VSM cells secrete VEGF raises the possibility that VSM
cells act as a source of VEGF that could function as a paracrine factor both to maintain
the integrity of the vascular endothelium and to repair endothelial damage. Since VEGF
binds heparin, locally synthesized VEGF might be stored in the extracellular matrix
bound to heparin-like molecules, as appears to occur with bFGF. Whether VSM cells
make VEGF in vivo remains to be confirmed by in situ hybridization or by immunohisto-
chemistry.
Binding sitesfor human VPFIVEGF on vascular endothelial cells
Specific binding ofhuman VPF/VEGF to a variety ofendothelial cells has now been
demonstrated by several investigators. Olander et al., in 1991, used highly purified gVPF
in cross-linking experiments to demonstrate '25I-gVPF-receptor complexes of two types
[125]. Mostofthe complexes migrated slowly in SDS-PAGE, indicating that they were of
very high molecular weight and probably highly cross-linked. A portion ofthe molecules
migrated as 270 kDa complexes, indicating that the molecular weight of the endothelial
cell VPF receptor is about230 kDa. In 1991, Myoken etal. purified VEGF to homogene-
ity from protein-free culture conditioned medium ofA-431 human epidermoid carcinoma
cells [126]. This VEGF was characterized as a homodimer composed of22 kDa subunits
with an N-terminal sequence that was similar to VEGFs produced by human HL60
leukemic and U937 histiocytic lymphoma cells. A431 VEGF was used to identify specif-
ic and saturable binding sites for VEGF on HUVEC. By affinity cross-linking, VEGF-
binding site complexes of230, 170, and 125 kDa were detected on human umbilical vein
endothelial cells (HUVEC). VEGF specifically induced the tyrosine phosphorylation ofa
190 kDa polypeptide, which was similar in mass to the largest binding site detected by
affinity cross-linking.
In 1992, Jakeman et al., using recombinant human VEGF (rhVEGF), showed the
colocalization of 125I-rhVEGF binding with Factor VIII-like immunoreactivity, thus
demonstrating binding sites associated with vascular endothelial cells ofboth fenestrated
and nonfenestrated microvessels as well as the endothelium oflarge vessels, while failing
to demonstrate evidence of displaceable binding on nonendothelial cells [127]. Specific
binding was associated with quiescent as well as proliferating vessels. Those findings
were thought to support the hypothesis that VEGF plays a specific role in both the main-
tenance and in the induction of growth of vascular endothelial cells. In the central ner-
vous system, 125I-rhVEGF binding sites were associated with Factor VIII immunoreactiv-
ity in arteries, veins, and microvessels. The density of bindng was greatest in the gray
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matter of the brain and spinal cord. In the cerebral cortex, the binding pattern followed
the distribution of penetrating vessels, extending from the outer meninges toward the
deeper laminae. Displaceable binding was also associated with the meninges and the
large vessels on the surface of the brain and spinal cord, and was seen along vascular ele-
ments in the choroid plexus. No binding was seen along the ependyma of the ventricles.
Examination of pituitary sections revealed binding in the pars distalis and pars nervosa,
while essentially no binding was seen in the poorly vascularized pars intermedia.
In 1992, Gitay-Goren et al. reported that VEGF binding to its cell surface receptors
was clearly dependent on the presence of cell surface-associated heparin-like molecules
[128]. Heparin, at concentrations ranging from 0.1 to 10 gg/ml, strongly potentiated the
binding of 125I-VEGF to its receptors on endothelial cells derived from the bovine aorta
and human umbilical vein. Scatchard analysis of 125I-VEGF binding indicated that
gg/ml heparin induces a 8-fold increase in the apparent density of high affinity binding
sites for VEGF, but does not significantly affect the dissociation constant of VEGF.
Cross-linking experiments showed that heparin strongly potentiates the formation of the
170-, 195-, and 225-kDa 125I-VEGF-receptor complexes on endothelial cells. At high 125I-
VEGF concentrations (4 ng/ml), heparin preferentially enhanced the formation of 170-
and 195-kDa complexes. Preincubation of the cells with heparin, followed by extensive
washes, produced a similar enhancement of subsequent125I-VEGF binding. The binding
of125I-VEGF was completely inhibited following digestion of endothelial cells with hep-
arinase and could be restored by the addition of exogenous heparin to the digested cells.
The enhancing effect of heparin facilitated the detection of VEGF receptors on cell types
that were not known previously to express such receptors (bovine granulosa cells, bovine
corneal endothelial cells). The results suggested that cell surface-associated heparin-like
molecules are required for the interaction of VEGF with its cell surface receptors.
Regulatory mechanisms involved in VPF expression
VPF/VEGF is highly expressed in areas of active vascular proliferation and in a vari-
ety of human tumor cell lines and also in many normal tissues. It is a heparin-binding
mitogen and permeability-inducing polypeptide structurally related to PDGF and existing
in four species which are generated by analogous alternative gene splicing. The extracel-
lular ligands and components of the signal transduction pathway which lead to VEGF
expression remain unclear. Isoenzymes ofPKC are thought to play an essential role in the
pathway leading to VPF/VEGF expression. Four AP-1 binding sites have been identified
in the promoter region of the VEGF gene. Phorbol ester treatment of vascular smooth
muscle cells and U937 cells induces VEGF mRNA expression. Transforming growth fac-
tor-Bl also causes a slight increase in VEGF mRNA in U937 cells. In 1992, Finkenzeller
et al. showed that both platelet-derived growth factor and phorbol ester cause an increase
in vascular endothelial growth factor (VEGF) mRNA expression in control NIH 3T3
fibroblasts and NIH 3T3 fibroblasts overexpressing human PKCa as compared to control
cells [129]. In cells stimulated with PDGF or phorbol ester, induction of expression was
lost after down-regulation of PKC. This indicates that PKC is involved in signal transduc-
tion leading to VEGF expression. Claffey et al. recently reported a series of experiments
employing phorbol esters, calcium ionophore, and cAMP analogues which demonstrated
that VEGF mRNA expression is stimulated in preadipocytes (3T3-F442A) by both PKC
and protein kinase A-mediated pathways. Their results suggest that VEGF mRNA levels
are closely linked to the process of cellular differentiation. They also demonstrated that
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PC12) by a mechanism possibly involving aberrant activation of cellular second messen-
ger pathways. The transformed undifferentiated cells express moderate levels of VEGF
mRNA whereas expression is essentially extinguished when the cells differentiated into
non-malignant neuron-like cells [130].
Additional insight into VEGF regulatory mechanisms derives from a report that stud-
iedfms-like tyrosine kinase (Flt) in Xenopus laevis oocytes. Flt is a transmembrane
receptor in the tyrosine kinase family. It was determined that Flt expression in oocytes
conferred specific high-affinity binding ofVPF/VEGF and caused the cells to release cal-
cium in response to VPF/VEGF, thus indicating that Flt encodes a receptor for
VPF/VEGF. The Flt transcript has also been detected in HUVEC that respond to
VPF/VEGF. Whether or not Flt is the only receptor for VPF/VEGF has yet to be deter-
mined. Similarly, it is not known whether the flt receptor is responsible for either perme-
ability or angiogenesis induction by VPF/VEGF [131]. A brief tabulation of documented
VPF/VEGF actions/activities has been provided (Table 8).
THE ROLE OF VPF IN TUMOR EDEMAGENESIS AND ANGIOGENESIS
Angiogenesis is a process by which new capillary structures are formed. The new
microvessels eventually coalesce, organize, and enlarge into larger vascular structures by
the process termed neovascularization. Examples of physiologic angiogenesis include the
cyclical development of the corpus lutemn and normal wound healing. Neovasculariza-
tion plays a critical, albeit self-limited, role in a variety ofpathological processes such as
arthritis, retrolental fibroplasia, atherogenesis, pyogenic granuloma, and keloid forma-
tion. Tumor-induced angiogenesis is subserviant to the metabolic needs of the neoplasm
which in turn is self-sustaining and not self-limited. Tumor cell replication continues pro-
vided a vascular network allowing for adequate nutrient delivery develops in parallel. It is
now apparent that tumor cells induce and control new vessel growth by secreting a vari-
ety offactors capable ofinducing endothelial cell migration and replication. Most notable
are a group of heparin-binding polypeptides which include acidic and basic FGF, and the
more recently defined VPF/VEGF. Copper ions and heparin likely play key roles as mod-
ulators or potentiators ofangiogenesis. VPF/VEGF is most novel for a variety ofreasons
including: (1) its dual role in permeability induction and angiogenesis (FGF has no per-
meability-inducing properties.); (2) its specific action on endothelial cells (FGF and other
non-VPF/VEGF angiogenesis factors act upon vascular smooth muscle cells and fibrob-
lasts as well as endothelial cells.); and (3) its active secretion by tumor cells (The
VPF/VEGF molecule possesses a peptide secretor sequence and unlike FGF does not rely
on cellular demise forrelease ofintracellular factor stores.)
The microvasculature ofbrain tumors displays several distinctive ultrastructural fea-
tures that allow ready distinguishment from normal cerebral microvessels. The presence
of widened endothelial cell junctions, discontinuous tight junctions, cellular membrane
fenestrations, noncontiguous basement membranes, active micropinocytosis, and paucity
of mitochondria, sharply contrast with normal blood-brain barrier endothelial cytoarchi-
tecture [12, 15, 16, 20, 21, 25, 35-37]. These features, which also typify endothelium lin-
ing the normal peripheral vasculature, have previously been associated with the water and
protein extravasation, and consequent cerebral edema that occurs with malignant brain
tumors [15, 17, 25, 132]. Like blood-brain barrier microvessels, however, the normal
peripheral vasculature is not inherently permeable to macromolecules. Nevertheless,
tumors occurring outside the central nervous system also exhibit microvascular extrava-
sation that is clinically manifested as malignant effusions, ascites, and tissue edema
[60-65].
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The nonnal peripheral vasculature is exquisitely sensitive to permeability-induction
by histamine, bradykinin, serotonin, prostaglandins, and a variety of other physiological
substances [44-46]. In contradistinction, normal cerebral microvessels are totally inca-
pable of responding to these substances when tested in situ. Similarly, HG-VPF, which
clearly is active in the guinea pig and rat cutaneous microvasculature, failed to evoke
extravasation of fluorescein-albumin, 125I-bovine serum albumin, or edema fluid as evi-
denced by tissue specific gravity determinations, when injected into normal rat brain.
However, injection of HG-VPF into C6 gliomas that had been implanted into rat brains
showed brain tumor microvessels to be capable ofresponding with increased permeabili-
ty in situ (unpublished observations, G. R. Criscuoloand E. H. Oldfield).
Vascular endothelial cells from peripheral and central nervous system sources are
known to possess a complex cytoskeletal architecture [101, 111]. The endothelial
cytoskeleton is composed ofactin, myosin, and tropomyosin proteins that serve to regu-
late cellularconfiguration. Therefore, cellular mobility and vascularpermeability arepro-
cesses that are likely to result from changes in intracellular calcium ions that occur in
response to angiogenesis factors and VPFs. Stimuli that induce cytosolic calcium tran-
sients and change endothelial cell shape, ultimately result in opening of interendothelial
junctions at the level of the postcapillary venule, which in turn results in vascular
extravasation [44, 84, 116]. Histamine-induced cytosolic calcium changes have been
shown to correlate with changes in endothelial F-actin content, and passage of albumin
across endothelial monolayers derived from human umbilical veins [115]. In fact, many
of the commonly recognized mediators of microvascular permeability have been shown
to induce transient elevations in endothelial cytosolic calcium, irrespective ofthe variety
of endothelial cell tested [44, 84, 112, 115]. Significantly, normal brain microvascular
endothelial cells are equally capable of responding with calcium ion transients, and, by
conjecture, cytoskeletal alterations that would culminate in vascular extravasation. These
findings, and the morphological similarities between brain tumor vessels and the normal
peripheral vasculature, suggestan alternative hypothesis for the induction ofvascular per-
meability in brain tumors.
Perhaps the reason BBB microvessels are incapable of responding to permeability
mediators in situ, relates solely to their interendothelialjunctions being physicallyjoined
together by continuous pentalaminar tight junctions. The extreme integrity of this junc-
tion is supported by experimental studies ofosmotic disruption of the BBB by mannitol,
wherein investigators showed the interendothelial clefts to be closed, and the tightjunc-
tions to be continuous and intact after exposure to that potent physical agent: opening of
thebarrierby mannitol was associated with an increased transgression ofmicropinocytot-
ic vessicles between the lumenal andablumenal endothelial surfaces [69]. Further support
derives from the knowledge that peritumoral brain edema eminates directly from the
tumor bed, and is not the result of HG-VPF induced extravasation in the surrounding
blood-brain barrier microvessels [54]. Therefore, one may reasonably put forth the
hypothesis; that an alteration or absence of such a critical component of BBB as the
interendothelial tightjunction may at once render brain tumor microvessels similar to the
peripheral microvasculature, both anatomically, and with respect to their ability to
respond to permeability mediators. As a result, brain tumor microvessels would be capa-
ble ofresponding to the HG-VPF secreted by surrounding tumor cells, and production of
vasogeniccerebral edema would result.
Although the study ofVPFs has already yielded valuable insight into a mechanism of
tumor-mediated vascularpermeability, many questions remain unanswered. Several ques-
tions pertinent to neoplastic brain edema immediately arise: Why does peritumoral brain
edema not follow an even more malignant course? If brain tumor microvessels remain
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constantly exposed to HG-VPF, and respond with a constant rate ofplasma extravasation,
why would a patient not succumb to a rampant increase in intracranial pressure within
perhaps minutes, hours, or a few days at most? This may be partly explained in part by
known mechanisms ofbrain edema resolution. Excess extracellular fluid normally travels
through the brain interstitium in a centripetal direction (toward the CSF-containing ven-
tricular system) by a passive process referred to as bulk flow. In addition, astrocytic cells
are known to be actively involved in the imbibition ofexcess tissue fluid. This issue may
be further explained by observations indicating that HG-VPF is capable of inducing a
period of unresponsiveness, refractoriness, or tachyphylaxis, whereby consecutively
applied stimuli will not result in cytosolic calcium changes or further vascular extravasa-
tion [60, 80, 83, 84]. Supporting this notion is the common occurrence ofaperiod ofrela-
tive unresponsiveness (refractory period) in many physiological cascades, as well as in a
variety ofphysiologically excitable cells (neurons, photoreceptor cells, musclecells).
EFFICACY OF DEXAMETHASONE FOR NEOPLASTIC BRAIN EDEMA
The clinical efficacy ofdexamethasone in the setting ofperitumoral brain edema has
been well described and documented [11, 48-56, 80, 83-86]. Clinical trials were initiated
by Kofman etal., who in 1957 reported remarkable temporary improvement in neurologi-
cal symptoms in 14 out of 22 patients with brain metastases from breast cancer treated
with prednisolone [133]. Galicich and French subsequently established a standard regi-
men of dexamethasone for primary and metastatic brain tumors and for postoperative
brain edema [11]. Using this treatment regime, patients will predictably improve within
8-24 hrs of the first intravenous dose and will subsequently resolve most of their signs
and symptoms within the next 2-5 days thereafter. Although significantresolution ofper-
itumoral edema is not often readily apparent on imaging studies, several investigators
have provided direct evidence ofreduction in both tumor enhancement and edema on CT
scans taken several days post initiation ofsteroid therapy [134, 135]. Positron emmission
tomography (PET) employing 68Gd as a tracer, has been used to demonstrate that
increased capillary permeability associated with brain tumors occurs only within the
tumor vascular bed and not in the adjacent brain tissue [136]. Furthermore, in studies
employing 82Rb as a PET tracer, Jardan et al., demonstrated that in patients receiving
high-dose dexamethasone treatment (100 mg i.v. followed by 24 mg every 6 hrs), the per-
meability constant (KI) decreased significantly in tumor tissue (mean of 30%) [137]. A
quantitative autoradiographic study reported by Austin et al., demonstrated that in a rat
C6 glioma model, capillary permeability of the tumor and adjacent brain decreased sig-
nificantly as early as 1 hr after administration of dexamethasone (10 mg/kg i.p.) [138].
Complementing these studies are reports indicating that (3H)-dexamethasone given intra-
veneously concentrates in the brain tumor bed. Moreover, steroid receptor studies have
demonstrated the occurrence of receptors in a variety of brain tumors, with the greatest
concentrations being observed in metastatic tumors. This is notable in view of the fact
that metastatic tumors are at once most likely to express the greatest amount of edema
and most likely to respond to dexamethasone therapy. These data support the hypotheses
that edema fluid emanates from the tumor's angiogenic vascularbed, and thatdexametha-
sone acts primarily by retarding the rate of edema fluid formation by a mechanism
involving steroid receptor binding. As a result, patients respond early to the consequent
reduction in both fluid extravasation and tissue pressure (ICP). Subsequently, and in a
more delayed fashion, CT- or MRI-evident edema will slowly resolve as normal physio-
logical mechanisms for clearing excess interstitial fluid prevail.
We have been able to demonstrate several specific levels at which dexamethasone
may specifically exert its beneficial effects in this focused pathophysiological setting
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[801. Concentrations of dexamethasone that occur in our patients' brain tumors will
specifically suppress production of HG-VPF by cultured human malignant glioma cells
[83]. This finding alone suggests a powerful mechanism for steroid efficacy. In addition,
a distinct and separate mechanism ofsteroid action may occur at the level ofthe key bio-
logical component for this process; the microvascular endothelial cell. This is supported
by the finding of calcium transient suppression by dexamethasone in cultured endothelial
cells [84]. Lastly, a glimpse into the mechanism by which dexamethasone effects target
cells (glioma cells and endothelial cells) is provided by the following findings: (1)
coinjection of HG-VPF with dexamethasone did not alter the extent of vascular extrava-
sation [80], (2) pretreatment oftest animals with dexamethasone 1-2 hrs before HG-VPF
injection substantially inhibited vascular extravasation whereas pretreatment less than 1
hr before resulted in no inhition of HG-VPF activity [80, 83, 85], (3) pretreatment of test
animals with actinomycin D before dexamethasone exposure resulted in significant,
albeit slightly reduced, HG-VPF induced extravasation [83]. The implication is that dex-
amethasone exerts its actions indirectly, by inducing de novo synthesis of a polypeptide
intermediary after receptor-mediated membrane traversal, rather than by nonspecific
membrane stabilization. This concept has been put forth as an explanation for the protec-
tive effect of dexamethasone in rats affected by global cerebral ischemia [139, 140].
Furthermore, a second messenger polypeptide, (variably referred to as "macrocortin",
"lipocortin", "endocortin", or "renocortin"), has been identified, characterized, and found
to mediate the effect of glucocorticoids by inhibition of phospholipase-A2 [140].
Induction of macrocortin synthesis requires steroid receptor occupation and de novo pro-
tein synthesis. It therefore appears possible that HG-VPF may act by inhibiting a rate-
limiting enzyme in the prostaglandin cascade (phospholipase-A2) [83-85]. This is cor-
roborated by the work of others who have shown prostaglandins to be potent inducers of
cytosolic calcium release in endothelial cells [141, 142].
Additional investigations using a completely purified vascular permeability factor
product are clearly warranted and should better define the kinetics, refractoriness to
sequential stimulation, and dose-responsiveness of VPF-induced microvascular extrava-
sation. Furthermore, comparison of endothelial cells derived from different anatomical
sources (brain, retina, lung, adrenal, umbilical cord), from differing sized vessels (arterial,
arteriolar, capillary, venous, venular), and from several species (human, bovine, rodent),
should determine the extent, and degree of specificity of VPF activity with regard to
these variables.
Information to date strongly favors a direct action of VPF on the vascular endothelial
cell. The rapid and reversible kinetics of VPF activity in vivo and in vitro, its remarkable
affinity for immobilized heparin, and its ability to induce significant changes in endothe-
lial cytosolic calcium lend solid support to, ifnot affirmation of, this premise [80, 83-85].
A well-defined negatively charged glycocalyx, composed primarily of sulfated gly-
cosaminoglycans, is present on capillary endothelial cell surfaces [101]. This cell coat is
largely composed of polyanionic heparan sulfate and sialic acid residues. Its primary
function is thought to be the selective regulation of endothelial cell binding and transcap-
illary passage ofmacromolecules. The cationic nature of the VPF molecule at physiologi-
cal pH would therefore suggest a means for direct, albeit nonspecific, electrostatic attrac-
tion of the VPF molecule to the endothelial cell surface. This in turn, would likely facili-
tate the subsequent binding and interaction between the active site on the VPF molecule
and a specific membrane receptor.
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sion of peritumoral brain edema. In addition, an explanation for the efficacy of dexam-
ethasone in the treatment of symptomatic brain edema associated with cerebral neo-
plasms is strongly suggested. The clinical and experimental findings are also supported
by the occurrence ofsteroid receptors in cerebral tumors [48-54], and the lack of steroid
efficacy in the setting of ischemic, toxic, hemorrhagic, and traumatic cerebral edema
[55-59]. Inhibition of VPF activity by glucocorticosteroids such as dexamethasone
appears to be related to highly specific actions at the cellular level (i.e., inhibition of
tumor cell expression of VPF, and inhibition of VPF-induced endothelial cell calcium
responses). Perhaps a better understanding of the subcellular mechanisms involved in
steroid-induced VPF inhibition, will suggest either worthwhile refinements in our use of
these agents, or the means to develop novel methods that are safer and more effective in
the treatment ofpatients with neoplastic vasogenic brain edema.
ONGOING STUDIES OF VPF IN BRAIN TUMOR EDEMAGENESIS AND
ANGIOGENESIS
Discussions in this section have grown out of experiments carried out in the Brain
Edema Research Laboratory of the Yale University School of Medicine, Section of
Neurological Surgery (submitted for publication in a work authored by John G. Strugar,
William N. Harrington, David Rothbart, and Gregory R. Criscuolo). Informal discussion
of our preliminary findings in this work is meant only to provide current ideological
insight for thereader, and is done with the mutual consentofall authors.
We are now in the process of immunostaining low grade and high grade human
gliomas with purified rabbit polyclonal IgG-anti-VPF/VEGF. Our goal is to further eluci-
date the role of VPF in neoplastic vasogenic brain edema and tumor cyst formation. To
study VPF in relation to angiogenic activity, immunostaining for von Willebrand factor,
an endothelial cell surface specific antigen, is performed and vessels are examined for
their number and morphological changes. Clinical correlation will then be made with
respect to VPF staining, the presence and extent of peritumoral brain edema, the occur-
rence offluid-filled tumorcysts, and tumor enhancement, using T2 weighted unenhanced
and gadolinium enhanced Ti weighted MRI images. Preliminary results indicate that the
presence or degree of VPF staining does not necessarily correlate with the tumor grade,
although higher grade lesions generally stained more consistently for VPF. Peritumoral
brain edema is quantitated andreported as an edema index (EI) derived from gadolinium-
enhanced Ti and T2-weighted MRI images. The magnitude of the edema index does not
appear to necessarily correlate with the intensity ofVPF staining. A significant difference
between the average EI of the positive and negative VPF groups has been noted. There is
a statistically significant difference between the negative VPF group and the two positive
VPF groups taken together. All tumors associated with large cysts have thus far stained
positively for VPF, despite the absence of apparent peritumoral white matter edema in
three of those lesions. The degree of gadolinium enhancement appeared to correlate to
some extent with tumor grade in that all high grade lesions demonstrated significant
enhancement, while most of the non-enhancing specimens were identified as gliosis or
low grade tumors did not. It is interesting to note however, that the four low grade lesions
which enhanced with gadolinium, also stained positively for VPF. These findings support
previously reported observations on the consistent occurrence of neovascularity and
blood-brain barrier disruption with malignant tumors. It has also been noted that certain
benign CNS tumors (low grade astrocytomas, neurilemmomas, hemangioblastomas, and
meningiomas) may also exhibit contrast enhancement, peritumoral edema, and tumorcyst
formation. Our preliminary results suggest, therefore, that the strongest correlation
appears neither to be between tumor grade and contrast enhancement, nor tumor grade
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and VPF expression per se, but rather a correlation between the occurrence of neovascu-
larization, edemagenesis, cyst formation, or tumor enhancement, and the expression of
the VPF molecule, irrespective of tumor type or grade. High grade tumors staining posi-
tively for VPF tended to have hypertrophic, hypercellular vessels, with vascular wall
thickening and proliferation. Positively staining low grade tumors exhibited a vascular
morphology intermediate between the gliosis or VPF-negative low grade lesions, and the
high grade tumors positive for VPF in that areas of quiescent appearing vessels were
intersperced with variable numbers ofhypertrophic, hypercellular vessels. Results of this
investigation suggest that tumor grade in itself does not necessarily correlate with pres-
ence or absence of VPF. The occurrence of peritumoral edema or tumor cysts appear to
correlate very well however, with presence ofVPFexpression.
The inclusion of tumor cysts as a form of edema or more accurately, an epiphe-
nomenon of microvascular extravasation is a relatively new concept deserving of some
discussion. Tumor cysts, unlike non-neoplastic intracranial cysts such as arachnoid or
leptomeningeal cysts which contain mainly CSF, have a large number of endogenous
cerebral as well as vasogenic proteins within their fluid. Among the endogenous cerebral
proteins present areGFAP, S-100 protein, and P-endorphin [143-146]. However, in tumor
cysts, it appears thatthese endogenous proteins representa minority, whereas greater than
92% of tumor cyst fluid protein is plasma derived [146]. The implication of this study is
that an increase in the permeability of the BBB takes place, allowing passage ofplasma
proteins into the cystic fluid. Furthermore, an electron micrograph examination ofa cys-
tic grade II-IIIgliomarevealed endothelial fenestrations in the capillaries lining the tumor
cyst identical to those present in patients with vasogenic cerebral edema associated with
solid tumors [146]. These data strongly suggests that both cerebral edema and tumor
cysts share a common pathway at the endothelial level, and that they may indeed repre-
sent dramatically different expressions of the same pathophysiology. All cystic lesions
examined thus far were associated with VPF staining, regardless of tumor grade. These
preliminary data appear to lend support to the view that tumor cysts and vasogenic edema
share a common pathophysiology involving VPF, angiogenesis and microvascular
extravasation.
Our primary aim is to examine the relationship between presence of VPF and vaso-
genic brain edema. However, we are also studying angiogenic manifestations in ourbrain
tumor specimens by looking at the number and morphology of tumor vessels. There is
extensive documentation on the angiogenic effects of VPF/VEGF. Connolly et al. [81]
has shown that VPF induces endothelial cellular proliferation in vitro, and angiogenesis
when administered into rabbit bone grafts and comeas in vivo. Microvessels are inade-
quately visualized with routine hematoxylin and eosin staining as they are mostly col-
lapsed in pathological specimens. Staining for factor VIII, however, takes advantage of
the fact thatendothelial cells uniformly express this factor and thus enhancing our assess-
ment of microvessels. This technique was used by Weidner et al. [147] who found a sig-
nificant correlation between vessel number, in staining breast cancer specimens, and
potential for metastasis. An increased number of vessels counted correlated positively
with a greater potential for metastasis. We are using a similar method to evaluate angio-
genesis in our brain tumor specimens. Preliminary results fail to indicate any correlation
between vessel number per se, and tumor grade, VPF staining, edema, or degree of
enhancement. Several possible explanations for this resulthave beenproposed. One is the
infiltrating nature of primary gliomas which invade surrounding tissue rather than dis-
place it. The tissue which the tumors invade is among the most abundantly vascularized
in the body, thus an infiltrating tumor would encounter nutrient supplies at frequent inter-
vals as it advances. This supply could support a fairly high rate of growth. When thatCriscuolo: Vascularpermeabilityfactorandneoplastic brainedema
growth becomes exuberant, as in highly malignant gliomas, in the absence of adequate
angiogenesis, necrosis occurs. Secondly, angiogenesis and malignancy may not always
correlate. There are multiple examples ofangiogenesis being presentprior to the onsetof
malignancy [148-150]. Alternatively, angiogenesis has also been reported to occur after
neoplasia has clearly developed [151]. However even if angiogenic forces are present, it
is unknown how they manifest themselves in brain tumors. Weidner found that in breast
cancer, metastatic potential correlated with an actual higher numberofvessels.
In brain tumors, which have very low metastatic potential, tumoraggressiveness may
notbemanifested by an actual increase in the numberofvessels, butratheras achange in
vessel morphology. The data we have presented are not conclusive, yet wecan confident-
ly report the observation that tumor vessels associated with VPF positive tumors
appeared morphologically altered as compared to the vessels in VPF negative tumors.
Vessel wall thickening and tortuosity, both features of our VPF positive samples, corre-
late with the experimental findings that VPF/VEGF induce increase in vascular perme-
ability, extravasation of fibrinogen and a formation of a fibrin rich perivascular area.
Finally, as mentioned earlier in the discussion, several types of VPF/VEGFs have been
isolated, each with somewhat different physiological activities. For instance, of the four
types ofVEGFs isolatedby expression cloning from ahuman cDNAlibrary, two (VEGF-
189 and VEGF-206) were found to exhibitsignificantly more potency in inducingperme-
ability in the Miles assay while demonstrating a markedly reduced mitogenic activity in
comparison to the other forms [100]. In specimens reviewed for this report, the finding
that permeability and morphological changes predominate, while mitogenesis does not,
may be determined by the type of VPF expressed. The data suggest that tumors exhibit-
ingvasogenic edema appear to express VPF.
Another avenue of research has been directed toward the suppression of tumor
growth through angiogenesis inhibition. A variety of hypervascular human tumors
including schwannomas, neurofibromas, and neurofibrosarcomas have been examined in
vivo by xenograft implantation into athymic nude mice. In one study employing neurofi-
brosarcoma xenografts, the effect of heparin and cortisone on tumor growth and neovas-
cularization was studied. The results were interesting in that heparin administration alone
stimulated angiogenesis and resulted in tumor growth greater than in the control group.
Hydrocortisone alone had a minimal effect on angiogenesis and caused a minimal reduc-
tion in tumor growth. Notably, heparin and cortisone administered together resulted in a
significant inhibition of both angiogenesis and tumor growth. [152] Tumor growth and
angiogenesis stimulation observed with heparin is interesting in view of in vitro studies
demonstrating that VEGF binding to its cell surface receptors was dependent upon cell
surface-associated heparin-like molecules. Furthermore, VEGF receptor expression and
detection was facilitated by exogenous heparin administration [128]. The absence of
angiogenesis and tumor growth inhibition when hydrocortisone alone was administered is
in keeping with global clinical experience indicating a specific action by the glucocorti-
coid dexamethasone on edema in the absense of tumor growth inhibition. A mechanism
for the synergistic effect of heparin and hydrocortisone against angiogenesis and tumor
growth has yet to bedetermined. A recent study employing AGM-1470, a potent, fungal-
derived inhibitor of angiogenesis, demonstrated the suppression of neovascularization
and tumor growth of benign and malignant human Schwann cell tumors implanted into
the subrenal capsule ofathymic nude mice. Although the molecular mechanism by which
AGM-1470 acts is poorly understood, a hypothetical action on basic fibroblast growth
factor (basic FGF) was proposed [153]. The mechanisms involved in angiogenesis modu-
lation are likely to be highly complex. The role of edemagenesis and angiogenesis
inhibitors relative to VPF/VEGF expression and action remains to be deciphered.
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CLOSING REMARKS
Patients with brain tumors can enjoy an extended functional survival relating largely
to aggressive surgical excision, radiotherapy, and chemotherapy. Certain brain tumors are
considered histologically and biologically benign, and therefore ostensibly curable.
Nevertheless, significant perioperative neurological morbidity can be associated with sur-
gical excision of these lesions. This largely relates to the occurrence of vasogenic brain
edema. One of the most significant therapeutic advances in neuro-oncology in the past
three decades has been the recognition of the efficacy of corticosteroids in the symp-
tomatic treatment of patients with brain tumors. Their salutory effects on intracranial
hypertension have resulted in better tolerance of both surgical and radiation therapies.
However, the extended use ofhigh-dose corticosteroids is frought with potential compli-
cations. Consequences of their long-term use include sodium and water retention, hyper-
tension, diabetes mellitus, sepsis related to impaired immune function, connective tissue
alterations, gastrointestinal ulceration, aseptic necrosis of the femur head, and altered
mentation including mania, psychotic depression, and euphoria. Investigation into the
precise mechanism by which steroids act to lessen peritumoral cerebral edema may even-
tually provide clinicians with safer and moreeffective therapeutic alternatives forpatients
afflicted with brain tumors. Ongoing investigations will continue to focus on the interre-
lationships between glucocorticoids, VPF/VEGF, and microvascular endothelial cells.
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